UroGen Pharma(NASDAQ) URGN

UroGen Pharma Ltd. treats rare urinary tract cancers. Its products help patients avoid painful surgeries. These solutions use special gel to deliver medicine.

Fighting Cancer Without Surgery

• Zusduri: Non-surgical medicine for adults with recurring low-grade bladder cancer, which is a type of cancer that stays in the inner lining of the bladder.
• Jelmyto: First-of-its-kind therapy used to treat rare tumors in the upper urinary tract, providing an alternative to kidney removal or major surgery.
• RTGel Technology: Proprietary gel that starts as a liquid but thickens at body temperature to keep medicine in contact with tissues for hours.
• UGN-103 and UGN-104: Next-generation versions of existing products currently in testing that aim to simplify manufacturing and improve patient convenience.

Recent Milestones and Next Steps

• Entered a development and supply agreement with medac in Jan. 2024 to create more efficient cancer drug formulations.
• Purchased UGN-501, an experimental virus-based cancer treatment, from IconOVir in Feb. 2025.
• Launched Zusduri commercially in the United States in late June 2025 following its approval by the Food and Drug Administration.
• Discontinued a research program for UGN-301 in Nov. 2025 to prioritize other pipeline projects with higher clinical potential.

A Different Way to Deliver Drugs

UroGen uses its RTGel technology to solve the problem of medicine washing out of the urinary tract too quickly. By turning drugs into a sustained-release gel, the company can extend treatment exposure from a few minutes to up to six hours.

Financial Progress in 2026

• Revenue was $123.4 million for the six-month period ended June 30, 2026. This figure rose from $44.5 million in the same period of 2025.
• Selling and marketing costs reached $65.1 million in the first half of 2026. This was up from $50.0 million in the first half of 2025.
• The company held $108.0 million in cash, cash equivalents, and marketable securities as of June 30, 2026.
• Market capitalization hit $1.9 billion in the second quarter of 2026. This represented a 183.5% increase from the previous year.
• A new $250 million loan facility was established in Feb. 2026 to refinance debt and provide working capital.

The Final Word

UroGen has evolved from a research organization into a commercial biotechnology company with multiple approved products and a focus on non-surgical care. Its proprietary delivery technology serves as the foundation for both its current sales and its future drug pipeline.